Compare NNNN & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | SDGR |
|---|---|---|
| Founded | 2021 | 1990 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2025 | 2020 |
| Metric | NNNN | SDGR |
|---|---|---|
| Price | $34.00 | $18.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.25 |
| AVG Volume (30 Days) | 34.4K | ★ 819.3K |
| Earning Date | 04-28-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $8,185,146.00 | ★ $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.46 |
| P/E Ratio | $662.94 | ★ N/A |
| Revenue Growth | 21.95 | ★ 32.90 |
| 52 Week Low | $5.18 | $15.99 |
| 52 Week High | $55.65 | $28.47 |
| Indicator | NNNN | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 51.45 |
| Support Level | $31.18 | $17.02 |
| Resistance Level | $35.55 | $19.44 |
| Average True Range (ATR) | 5.14 | 0.79 |
| MACD | 0.14 | 0.15 |
| Stochastic Oscillator | 37.79 | 52.48 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.